CD274 and neoplasm: In vitro experiments removing dLN before receiving ICB inhibitors already show extremely poor regression of the primary tumor (32, 33), while in situ injection of anti-PD-L1 inhibitors to the dLN demonstrates similar efficacy compared with intravenous injection.